24 February 2017 - If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.

Shire announces that the CHMP of the EMA has adopted a positive opinion recommending the granting of conditional marketing authorisation for Natpar (rhPTH[1-84]), a recombinant human protein with the full length 84–amino-acid sequence of endogenous parathyroid hormone, as an adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

Read Shire press release